<DOC>
	<DOC>NCT02998528</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of nivolumab and ipilimumab compared to chemotherapy in the treatment of Early Stage Non-Small Cell Lung Cancer.</brief_summary>
	<brief_title>A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Early stage IBIIIA, operable nonsmall cell lung cancer, confirmed in tissue Lung function capacity capable of tolerating the proposed lung surgery Eastern Cooperative Oncology Group (ECOG) Performance Status of 01 Available tissue of primary lung tumor Presence of locally advanced, inoperable or metastatic disease Participants with active, known or suspected autoimmune disease Prior treatment with any drug that targets T cell costimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>